About
Before emerging therapies can be approved for widespread public use, they must first be tested in controlled clinical research settings like this one. By joining this Skin Lupus study, participants are playing a vital role in helping doctors and scientists make meaningful progress in the field of cutaneous lupus erythematosus (CLE) research, and helping to better understand autoimmune conditions and inflammation’s effect on the body.
What Is Being Tested?
During this gleam clinical trial, the research team will be studying the ability of the study drug (IMVT-1402) to help treat the symptoms of cutaneous lupus erythematosus (CLE), which is an autoimmune disease. Normally, antibodies identify foreign substances in the body, such as bacteria or viruses, so they can be removed. People with autoimmune diseases produce harmful ‘autoantibodies’ which are antibodies that attack the person’s own cells by mistake. Research indicates that in people with Skin Lupus, these harmful autoantibodies may attack healthy skin cells and cause the chronic inflammation seen in the skin. IMVT-1402 is designed to help reduce levels of certain antibodies in the blood, including the harmful autoantibodies which are thought to cause Skin Lupus. It is hoped that this may potentially alleviate symptoms in people with Skin Lupus. Read our FAQs to learn more about this study, and what to expect as a participant.
What Are the Benefits?
From the Community…
even just a little bit."
Clinical Trials Make A Difference
When you participate in a clinical study, you provide valuable information that could eventually lead to a better treatment and—with the right breakthrough—to better outcomes. Take our brief survey to see if you are a good fit. There is no obligation.
Participate in Innovation
Help Others
Shape the Future
Still have questions?
Contact us anytime at help@clinicalenrollment.com